Small molecule · developed by NEUROCRINE BIOSCIENCES
NBI-921352 is a small-molecule inhibitor of the sodium channel Nav1.6, encoded by SCN8A. It is being studied for the treatment of SCN8A developmental and epileptic encephalopathy syndrome, a severe neurological disorder caused by mutations in the SCN8A gene.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05226780 | Phase 2 | SCN8A Developmental and Epileptic Encephalopathy Syndrome | Terminated | NBIX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
SCN8A Developmental and Epileptic Encephalopathy Syndrome
See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NBIX catalysts and pipeline →